DOD Lung Cancer, Concept Award
ID: 353169Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353169
Timeline
    Description

    The Department of the Army, through the U.S. Army Medical Research and Materiel Command (USAMRAA), is inviting applications for the Fiscal Year 2024 Lung Cancer Research Program (LCRP) Concept Award, aimed at funding innovative and high-risk research projects that advance the understanding and treatment of lung cancer. The program seeks to support groundbreaking studies that provide new insights, technologies, or applications in lung cancer, with a particular emphasis on relevance to military health and addressing health disparities. With an estimated total program funding of $1.92 million, the LCRP expects to make approximately ten awards, and key deadlines include a pre-application submission by May 28, 2024, and a full application deadline by June 17, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.

    Point(s) of Contact
    help@eBRAP.org
    Files
    Title
    Posted
    HT942524LCRPCA-GG.pdf
    The Department of Defense (DOD) is seeking applications for the Fiscal Year 2024 Lung Cancer Research Program (LCRP) Concept Award, which aims to fund innovative and high-risk research to advance lung cancer treatment and management. The program is part of the Congressionally Directed Medical Research Programs and will have a funding availability of $25 million, expected to support ten awards. Key deadlines include a pre-application submission by May 28, 2024, and a full application deadline by June 17, 2024. All applicants must address at least one of the identified Areas of Emphasis, including health disparities, cancer biology, prevention, detection, and treatment strategies. Eligibility is open to both intramural and extramural organizations, and Principal Investigators must hold a postdoctoral or equivalent position. Notably, research focused on mesothelioma is not accepted, and applications must emphasize relevance to military health. The funding mechanism is structured to foster groundbreaking research that may tend to develop detailed insights and methodologies applicable to lung cancer. Throughout the review process, applications will be assessed for innovation, impact, and research strategy, with a strong focus on delivering preliminary data that furthers future investigations in lung cancer research.
    Similar Opportunities
    DOD Glioblastoma, Hypothesis Development Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the Fiscal Year 2024 Glioblastoma Hypothesis Development Award, aimed at funding innovative research to improve glioblastoma patient outcomes. This grant supports exploratory projects that address significant issues in glioblastoma research, particularly in areas such as drug delivery and biomarker identification, without requiring preliminary data. The total estimated funding for this program is approximately $4.64 million, with an expected 13 awards to be made, each with a funding limit of $200,000 for single principal investigators and $300,000 for partnering teams, over a performance period of up to two years. Interested applicants must submit a Letter of Intent by November 6, 2024, followed by a full application by November 20, 2024; for further inquiries, contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507.
    Toxic Exposures Translational Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Toxic Exposures Translational Research Award (TRA) to support research on adverse health outcomes related to military toxic exposures. This grant aims to facilitate translational research that bridges basic science and clinical applications, focusing on developing diagnostics, treatment strategies, and understanding exposure mechanisms to improve health care for service members and their families. With an estimated total program funding of $12.8 million and the expectation of awarding six grants, applicants must submit a pre-application by August 13, 2024, followed by a full application due by November 7, 2024. For further inquiries, interested parties can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DOD Glioblastoma, Resource Development Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the Fiscal Year 2024 Glioblastoma Resource Development Award, aimed at enhancing research capabilities for glioblastoma, a malignant brain tumor. This grant supports the development of preclinical model systems that improve the understanding and treatment of glioblastoma, with a focus on innovative approaches such as animal models, organoids, and patient-derived xenografts. With a total funding pool of $4 million, the program anticipates awarding up to five grants, each capped at $500,000 over three years. Interested applicants must submit a pre-application by November 6, 2024, followed by a full application due by November 20, 2024, and can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    Toxic Exposures Clinical Trial Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering a funding opportunity for the Fiscal Year 2024 Toxic Exposures Clinical Trial Award under the Toxic Exposures Research Program (TERP). This grant aims to support the rapid implementation of clinical trials that address health outcomes related to military-related toxic exposures, with a focus on prevention, treatment, and management of associated symptoms and diseases. The program emphasizes the importance of collaboration between the Department of Defense and the Department of Veterans Affairs, seeking proposals that align with specific program goals and topic areas, such as neurotoxin exposure and Gulf War Illness. The total estimated funding for this initiative is $10.4 million, with applications due by November 7, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    Toxic Exposures Investigator-Initiated Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Toxic Exposures Investigator-Initiated Research Award (TERP IIRA) to support research addressing health outcomes related to military-related toxic exposures. This grant aims to fund studies that contribute significantly to understanding and improving patient care for diseases associated with such exposures, encompassing all research phases from basic laboratory studies to translational research involving human subjects and animal models. With an estimated total program funding of $3.2 million and the expectation of awarding four grants, interested applicants must submit pre-applications by August 13, 2024, and full applications by November 7, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    Notice of Intent to Publish a Funding Opportunity Announcement for Scaling-up and Maintaining Evidence-based Interventions to Maximize Impact on Cancer (SUMMIT)- Lung Cancer Screening (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for the Scaling-up and Maintaining Evidence-based Interventions to Maximize Impact on Cancer (SUMMIT) initiative, specifically targeting Lung Cancer Screening (LCS). This initiative aims to fund up to three research projects that will develop and test strategies to enhance the delivery and sustainability of high-quality, guideline-concordant lung cancer screening among high-risk populations. The total estimated funding for this program is $2,400,000, with awards structured as Cooperative Agreements under the UG3/UH3 activity code, requiring clinical trials. The NOFO is anticipated to be published in late Summer 2024, with applications due in late Fall 2024, and the estimated award date is set for July 1, 2025. Interested applicants are encouraged to prepare by reviewing related materials and attending a pre-application webinar, details of which will be announced following the NOFO publication.
    DoD VRP, Clinical Trial Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), is offering the FY24 Vision Clinical Trial Award to fund innovative clinical trials aimed at addressing eye injuries and visual dysfunctions related to military service. This grant opportunity supports early-phase clinical trials that evaluate new products, pharmacologic agents, and devices, with a focus on improving treatment outcomes for service-connected visual impairments. With an estimated total program funding of $2.56 million and an anticipated award amount of up to $1.6 million per application, interested applicants must submit their pre-applications by July 11, 2024, and full applications by November 8, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DoD VRP, Translational Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Vision Translational Research Award (VRP TRA) to support innovative translational research aimed at advancing the prevention, diagnosis, and treatment of eye injuries and visual dysfunction associated with military service. This grant opportunity encourages projects that establish a clear path for transforming promising discoveries into clinical applications, including new drugs and devices, with a focus on collaboration with regulatory experts to facilitate the approval process. With an estimated total program funding of $1.6 million and the expectation of one award, interested applicants must submit a pre-application by July 11, 2024, followed by a full application by November 8, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DoD VRP, Investigator-Initiated Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Vision Research Program (VRP) Investigator-Initiated Research Award, aimed at advancing research on eye injuries related to military service. This grant opportunity seeks innovative proposals that address the understanding, prevention, diagnosis, and treatment of eye injuries associated with military exposure, with two funding levels available to accommodate projects at different stages of maturity. The program emphasizes the importance of improving care for service members and veterans affected by visual injuries, with an estimated total funding of $832,000 and the expectation of awarding approximately seven grants. Interested applicants must submit a pre-application by July 11, 2024, followed by a full application due by November 8, 2024; for further inquiries, contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    Black Lung Data and Resource Center Program
    Active
    Health Resources and Services Administration
    The Health Resources and Services Administration (HRSA) is forecasting a federal grant opportunity for the Black Lung Data and Resource Center Program, aimed at enhancing patient-level data collection and analysis for the Black Lung Clinics Program (BLCP). The program seeks to improve the operational efficiencies and service quality provided to U.S. coal miners suffering from respiratory diseases, particularly those related to Coal Mine Dust Lung Diseases (CMDLD). With an estimated total funding of $125,000 and the expectation of one award, the project is set to commence on July 1, 2025, following a synopsis posting on October 16, 2024, and closing on January 14, 2025. Interested applicants can reach out to Anna Feins at (301) 287-0251 or via email at blacklung@hrsa.gov for further information.